Griesel Mirko, Seraphin Tobias P, Mezger Nikolaus C S, Hämmerl Lucia, Feuchtner Jana, Joko-Fru Walburga Yvonne, Sengayi-Muchengeti Mazvita, Liu Biying, Vuma Samukeliso, Korir Anne, Chesumbai Gladys C, Nambooze Sarah, Lorenzoni Cesaltina F, Akele-Akpo Marie-Thérèse, Ayemou Amalado, Traoré Cheick B, Wondemagegnehu Tigeneh, Wienke Andreas, Thomssen Christoph, Parkin Donald M, Jemal Ahmedin, Kantelhardt Eva J
Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University, Halle-Wittenberg, Germany.
Clinical Trials Service Unit & Epidemiological Studies Unit, Department of Medicine, University of Oxford, Oxford, United Kingdom.
Oncologist. 2021 May;26(5):e807-e816. doi: 10.1002/onco.13718. Epub 2021 Mar 10.
Cervical cancer (CC) is the most common female cancer in many countries of sub-Saharan Africa (SSA). We assessed treatment guideline adherence and its association with overall survival (OS).
Our observational study covered nine population-based cancer registries in eight countries: Benin, Ethiopia, Ivory Coast, Kenya, Mali, Mozambique, Uganda, and Zimbabwe. Random samples of 44-125 patients diagnosed from 2010 to 2016 were selected in each. Cancer-directed therapy (CDT) was evaluated for degree of adherence to National Comprehensive Cancer Network (U.S.) Guidelines.
Of 632 patients, 15.8% received CDT with curative potential: 5.2% guideline-adherent, 2.4% with minor deviations, and 8.2% with major deviations. CDT was not documented or was without curative potential in 22%; 15.7% were diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IV disease. Adherence was not assessed in 46.9% (no stage or follow-up documented, 11.9%, or records not traced, 35.1%). The largest share of guideline-adherent CDT was observed in Nairobi (49%) and the smallest in Maputo (4%). In patients with FIGO stage I-III disease (n = 190), minor and major guideline deviations were associated with impaired OS (hazard rate ratio [HRR], 1.73; 95% confidence interval [CI], 0.36-8.37; HRR, 1.97; CI, 0.59-6.56, respectively). CDT without curative potential (HRR, 3.88; CI, 1.19-12.71) and no CDT (HRR, 9.43; CI, 3.03-29.33) showed substantially worse survival.
We found that only one in six patients with cervical cancer in SSA received CDT with curative potential. At least one-fifth and possibly up to two-thirds of women never accessed CDT, despite curable disease, resulting in impaired OS. Investments into more radiotherapy, chemotherapy, and surgical training could change the fatal outcomes of many patients.
Despite evidence-based interventions including guideline-adherent treatment for cervical cancer (CC), there is huge disparity in survival across the globe. This comprehensive multinational population-based registry study aimed to assess the status quo of presentation, treatment guideline adherence, and survival in eight countries. Patients across sub-Saharan Africa present in late stages, and treatment guideline adherence is remarkably low. Both factors were associated with unfavorable survival. This report warns about the inability of most women with cervical cancer in sub-Saharan Africa to access timely and high-quality diagnostic and treatment services, serving as guidance to institutions and policy makers. With regard to clinical practice, there might be cancer-directed treatment options that, although not fully guideline adherent, have relevant survival benefit. Others should perhaps not be chosen even under resource-constrained circumstances.
宫颈癌(CC)是撒哈拉以南非洲(SSA)许多国家最常见的女性癌症。我们评估了治疗指南的依从性及其与总生存期(OS)的关联。
我们的观察性研究涵盖了八个国家的九个基于人群的癌症登记处:贝宁、埃塞俄比亚、科特迪瓦、肯尼亚、马里、莫桑比克、乌干达和津巴布韦。每个登记处选取了2010年至2016年诊断的44 - 125名患者的随机样本。评估了癌症导向治疗(CDT)对美国国立综合癌症网络(NCCN)指南的依从程度。
632名患者中,15.8%接受了具有治愈潜力的CDT:5.2%完全依从指南,2.4%有轻微偏差,8.2%有严重偏差。22%的患者未记录CDT或其无治愈潜力;15.7%被诊断为国际妇产科联盟(FIGO)IV期疾病。46.9%的患者未评估依从性(未记录分期或随访情况的占11.9%,记录未找到的占35.1%)。完全依从指南的CDT比例在内罗毕最高(49%),在马普托最低(4%)。在FIGO I - III期疾病患者(n = 190)中,轻微和严重的指南偏差与OS受损相关(风险率比[HRR]分别为1.73;95%置信区间[CI],0.36 - 8.37;HRR,1.97;CI,0.59 - 6.56)。无治愈潜力的CDT(HRR,3.88;CI,1.19 - 12.71)和未接受CDT(HRR,9.43;CI,3.03 - 29.33)的患者生存率明显更差。
我们发现,在撒哈拉以南非洲,每六名宫颈癌患者中只有一名接受了具有治愈潜力的CDT。尽管疾病可治愈,但至少五分之一甚至可能多达三分之二的女性从未接受过CDT,导致OS受损。增加放疗、化疗和手术培训方面的投入可能会改变许多患者的致命结局。
尽管有包括依从指南治疗宫颈癌(CC)在内的循证干预措施,但全球生存率仍存在巨大差异。这项全面的跨国基于人群的登记研究旨在评估八个国家的疾病呈现、治疗指南依从性和生存现状。撒哈拉以南非洲的患者多在晚期就诊,治疗指南依从性极低。这两个因素都与不良生存相关。本报告警示撒哈拉以南非洲的大多数宫颈癌女性无法获得及时、高质量的诊断和治疗服务,为机构和政策制定者提供了指导。关于临床实践,可能存在一些癌症导向治疗方案,虽然不完全依从指南,但具有相关的生存益处。而其他一些方案,即使在资源有限的情况下也可能不应被选择。